In recent epidemiological and intervention studies, vitamin E has been found to be effective for coronary ar tery disease as an antioxidant and a free radical scav enger (1-3). Because vitamin E is freely available, some people may self medicate with megadoses of this vita min, so it is important to confirm the safety of high-dose vitamin E supplementation. Among the adverse effects of vitamin E, Corrigan has documented abnormal coag ulation after vitamin E supplementation in a patient on warfarin therapy (4,5). Vitamin E is also known to in fl uence platelet aggregation both in vitro (6) and in vivo (7). Since these findings indicate that vitamin E can promote a bleeding tendency, careful attention should be paid to the effects of high-dose supplementation. A recent double-blind randomized control trial showed that treatment with vitamin E at 400IU per d for a mean of 4.5y had no apparent effect on the car diovascular outcome (8). However, vitamin E may be more effective when administered at higher doses, be cause 400IU or 800IU per d of vitamin E was effective for the prevention of cardiac stroke in high-risk patients (3). Previous investigators have reported on the safety of vitamin E (9-11), but few have assessed its safety at doses of 1,200IU or more. In the present study, we ad ministered 1,200IU of vitamin E daily for 28d to healthy adult volunteers, and investigated the effects on blood coagulation and platelet aggregation.
SUBJECTS AND METHODS
Subjects. Twenty-two healthy adult male volun teers were enrolled in this study. Fourteen were as signed to the vitamin E supplemented group (VE group), and the other eight formed the control group. The mean age was 29.3 (SD 3.4)y in the VE group and 27.0 (SD 1.2)y in the control group, and mean body Analysis. Vitamin E concentrations in plasma and platelets were measured by the use of HPLC with elec trochemical detection, as described previously (12). The complete blood count, biochemical parameters, pro thrombin time (PT), activated partial thrombin time (APTT), hepaplastin test (HPT), factor XIII, and platelet aggregation were all assessed in the laboratory of our college hospital. Coagulation and platelet aggregation were assessed by the use of an STA (Roche Diagnostics K.K., Tokyo, Japan) and a HEMA TRACER 601 (MC Medical, Inc., Tokyo, Japan), respectively. Aggregation was induced by adenosine diphosphate (ADP) and col lagen, and the results were expressed as the maximum aggregation rate. ulation parameters such as PT, APTT, HPT, and factor XIII. ADP-induced platelet aggregation decreased dur ing the study period, but there was no significant differ ence between the VE group and the control group. The administration of vitamin E had no side effects, such as fever, rash, or gastrointestinal symptoms, and no ab normal data was found in the complete blood count and biochemical parameters of the VE group during the study period (Table 2) .
DISCUSSION
Vitamin E is a fat-soluble antioxidant, which is known to be effective and safe for the prevention of ath erosclerosis, and it has also been reported to decrease the incidence of ischemic heart disease (1-3). The pro phylactic administration of high-dose vitamin E to pre mature infants is also known to be effective for de creasing the incidence of retinopathy of prematurity. However, high-dose vitamin E is associated with a high incidence of sepsis and necrotizing enterocolitis in in fants having a birth weight of 1,500g or less (13); therefore the Committee on the Fetus and Newborn of the American Academy of Pediatrics has indicated that routine use of high-dose vitamin E in premature infants should not be recommended (14) . Although this ad verse effect has occurred only in premature infants, care is needed not only for premature infants, but also for other individuals on high doses of vitamin E. Vitamin E is known to suppress platelet aggregation, and the mechanism involved is speculated to be a de creased production of thromboxane A2 by the suppres sion of platelets cyclooxygenase (18). Lake et al, re ported that the increased platelet aggregability seen in vitamin E-deficient children was improved by vitamin E supplementation (7). The lack of significant alteration of platelet aggregation in the present study might sug gest that high-dose vitamin E had no effect on platelet function in normal healthy adults. The ADP-aggrega tion values of all subjects were altered within a normal range; however, a clarification of why this tendency to decrease is required, and may be accomplished by an increase in subjects.
A megadose administration of vitamin E is known to decrease vitamin K-dependent coagulation. Chicks given high doses of vitamin E showed a prolonged pro thrombin time, and this change was prevented by the administration of vitamin K (19). Corrigan has reported an adverse influence of vitamin E in patients receiving warfarin therapy (4,5), though another study was un able to confirm this (20) . In the present study, vitamin E did not affect PT, APTT, or HPT, suggesting that a sup plementation with 1,200IU per d is safe for the coagu lation system. Factor XIII also showed no significant changes during the study period.
In conclusion, the daily ingestion of 1,200IU of vita min E for 28d had no adverse effects in healthy men. We consider that a supplementation with 1,200IU of vitamin E is apparently safe, but further studies are re quired, including the administration for a longer period and the effects on females and the elderly. 
